LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential

被引：3
|
作者：
Xu, Xiaoling [1 ]
Li, Huihui [2 ]
Xie, Mingying [1 ]
Zhou, Zichao [1 ]
Wang, Ding [1 ,2 ]
Mao, Weimin [1 ,2 ,3 ,4 ]
机构：
[1] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp,Key Lab Diag, Hangzhou 310022, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China
[3] Zhejiang Canc Hosp, Zhejiang Canc Res Inst, Dept Thorac Surg, Hangzhou, Zhejiang, Peoples R China
[4] Chinese Acad Sci, Inst Canc & Basic Med IBMC, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 186卷
关键词：
Malignant pleural mesothelioma; Long non-coding RNA; Therapeutic target; LONG NONCODING RNA; CANCER-CELLS; C-MYC; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; DNA METHYLATION; BAP1; PROLIFERATION; ASBESTOS; PROMOTES;
D O I：
10.1016/j.critrevonc.2023.104012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Malignant pleural mesothelioma (MPM) is a rare but invasive cancer, which mainly arises from mesothelial tissues of pleura, peritoneum and pericardium. Despite significant advances in treatments, the prognosis of MPM patients remains poor, and the 5-year survival rate is less than 10%. Therefore, it is urgent to explore novel therapeutic targets for the treatment of MPM. Growing evidence has indicated that long non-coding RNAs (lncRNAs) potentially could be promising therapeutic targets for numerous cancers. In this regard, lncRNAs might also potentially therapeutic targets for MPM. Recent advances have been made to investigate the molecular basis of MPM. This review first provides a comprehensive overview of roles of lncRNAs in MPM and then discusses the relationship between molecular basis of MPM and MPM-related lncRNAs to implement them as promising therapeutic targets for MPM.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] The Molecular Basis of Malignant Pleural Mesothelioma
    Wadowski, Benjamin
    De Rienzo, Assunta
    Bueno, Raphael
    THORACIC SURGERY CLINICS, 2020, 30 (04) : 383 - 393
  • [2] Prognosis related clinical and molecular factors in malignant pleural mesothelioma
    王玉艳
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (02) : 76 - 77
  • [3] Molecular pathways in malignant pleural mesothelioma
    Whitson, Bryan A.
    Kratzke, Robert A.
    CANCER LETTERS, 2006, 239 (02) : 183 - 189
  • [4] Potential Value of Molecular Markers in Pleural Fluid for Differential Diagnosis of Malignant Pleural Mesothelioma
    Fujimoto, Nobukazu
    Asano, Michiko
    Fuchimoto, Yasuko
    Ono, Katsuichiro
    Ozaki, Shinji
    Kishimoto, Takumi
    CHEST, 2013, 144 (04)
  • [5] Trends and challenges in treatment of malignant pleural mesothelioma
    Tsiouris, Athanasios
    Kourliouros, Antonios
    Smith, E. E. John
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (06) : 312 - 313
  • [6] Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
    Moro, Jacopo
    Sobrero, Simona
    Cartia, Carlotta Francesca
    Ceraolo, Simona
    Rapana, Roberta
    Vaisitti, Federico
    Ganio, Stefano
    Mellone, Federica
    Rudella, Stefano
    Scopis, Federico
    La Paglia, Danilo
    Cacciatore, Carola Crystel
    Ruffini, Enrico
    Leo, Francesco
    DIAGNOSTICS, 2022, 12 (12)
  • [7] Rearrangement-related peptides with neoantigenic potential in malignant pleural mesothelioma
    Mansfield, Aaron S.
    Peikert, Tobias
    Smadbeck, James B.
    Udell, Julia B.
    Kosari, Farhad
    Murphy, Stephen J.
    Ren, Hongzheng
    Serla, Vishnu V.
    Klein, Janet L. Schaefer
    Karagouga, Giannoula
    Harris, Faye R.
    Sosa, Carlos
    Johnson, Sarah H.
    Nevala, Wendy
    Markovic, Svetomir N.
    Bungum, Aaron O.
    Edell, Eric S.
    Dong, Haidong
    Cheville, John C.
    Aubry, Marie Christine
    Jen, Jin
    Vasmatzis, George
    CANCER RESEARCH, 2018, 78 (13)
  • [8] MESOMARK™:: A potential test for malignant pleural mesothelioma
    Beyer, Heather L.
    Geschwindt, Ryan D.
    Glover, Curtis L.
    Tran, Ly
    Hellstrom, Ingegerd
    Hellstrom, Karl-Erik
    Miller, M. Craig
    Verch, Thorsten
    Allard, W. Jeffrey
    Pass, Harvey I.
    Sardesai, Niranjan Y.
    CLINICAL CHEMISTRY, 2007, 53 (04) : 666 - 672
  • [9] Diagnostic potential of microRNAs in malignant pleural mesothelioma
    Andersen, M.
    Grauslund, M.
    Ravn, J.
    Sorensen, J. B.
    Andersen, C. B.
    Santoni-Rugiu, E.
    APMIS, 2012, 120 : 17 - 17
  • [10] Integrative Molecular Characterization of Malignant Pleural Mesothelioma
    Hmeljaki, Jutija
    Sanchez-Vega, Francisco
    Hoadley, Katherine A.
    Shih, Juliann
    Stewart, Chip
    Heiman, David
    Tarpeyg, Patrick
    Danitova, Ludmila
    Drill, Esther
    Gibb, Ewan A.
    Bowlby, Reanne
    Kanchil, Rupa
    Osmanbeyoglull, Hatice U.
    Sekido, Yoshitaka
    Takeshita, Jumpei
    Newton, Yulia
    Graim, Kiley
    Gupta, Manaswi
    Gaylg, Cart M.
    Diaol, Lixia
    Gibbs, David L.
    Thorsson, Vesteinn
    Lype, Lisa
    Kanthetir, Havish
    Severson, David T.
    Ravegnini, Gloria
    Desrneules, Patrice
    Jungbluth, Achim A.
    Travis, William D.
    Dacic, Sanja
    Chirieac, Lucian R.
    Galateau-Salle, Francoise
    Fujimoto, Junya
    Husain, Aliya N.
    Silveira, Henrique C.
    Rusch, Valerie W.
    Rintoul, Robert C.
    Pass, Harvey
    Kindler, Heciy
    Zauderer, Marjorie G.
    Kwiatkowski, David J.
    Bueno, Raphael
    Tsaols, Anne S.
    Creaney, Jenette
    Lichtenberg, Tara
    Leraas, Kristen
    Bowen, Jay
    Felau, Ina
    Zenklusen, Jean Claude
    Akbanil, Rehan
    CANCER DISCOVERY, 2018, 8 (12) : 1548 - 1565
12345